# HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.

> **NCT05154851** · — · NO_LONGER_AVAILABLE · sponsor: **Hope Biosciences Research Foundation**

## Conditions studied

- Congenital Muscular Dystrophy Due to Lamin A/C Mutation

## Interventions

- **BIOLOGICAL:** HB-adMSCs

## Key facts

- **NCT ID:** NCT05154851
- **Lead sponsor:** Hope Biosciences Research Foundation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05154851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05154851, "HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05154851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*